Indirect hyperbilirubinemia with indinavir.
No Thumbnail Available
Date
2002-10-06
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).
Description
Keywords
Citation
Satija P, Parikh F, Aggarwal V, Sharma B, Hakim A, Pai-Dhungat JV. Indirect hyperbilirubinemia with indinavir. Journal of the Association of Physicians of India. 2002 Oct; 50(): 1316-7